Thiele Holger, Jobs Alexander
Klinik für Innere Medizin/Kardiologie, Herzzentrum Leipzig - Universität Leipzig, Strümpellstr. 39, 04289, Leipzig, Deutschland.
Herz. 2021 Feb;46(1):3-13. doi: 10.1007/s00059-020-05002-1.
The European Society of Cardiology (ESC) guidelines for the management of acute coronary syndrome without persistent ST-segment elevation (NSTE-ACS) published in August 2020, replace the former NSTE-ACS guidelines published in 2015. These updated guidelines have some relevant changes for the clinical practice, which include the diagnostic work-up, risk stratification, antithrombotic therapy, invasive or noninvasive coronary diagnostics and also long-term treatment. New sections deal with spontaneous coronary artery dissection (SCAD), myocardial infarction with nonobstructive coronary arteries (MINOCA) and also newly introduced quality indicators for NSTE-ACS treatment. The diagnostic work-up using highly sensitive cardiac troponin (hs-cTn) assays is emphasized with the recommendation to use fast triage decisions that enable an early rule-in (no STEMI) or rule-out (NSTEMI probable) in the emergency room or chest pain unit. In antiplatelet therapy a greater individualization of the treatment concept is recommended based on the individual ischemic/thrombotic events and bleeding complications. Some new aspects were introduced for timing of invasive coronary angiography; however, principally the very high-risk group should still immediately undergo coronary angiography and the high-risk group should undergo an invasive angiography within 24 h. In risk stratification, the former intermediate risk group has been removed, instead it is now emphasized that low-risk patients should be treated similarly to patients with chronic coronary syndrome.
欧洲心脏病学会(ESC)于2020年8月发布的非持续性ST段抬高型急性冠状动脉综合征(NSTE-ACS)管理指南取代了2015年发布的前版NSTE-ACS指南。这些更新后的指南在临床实践方面有一些相关变化,包括诊断检查、风险分层、抗栓治疗、有创或无创冠状动脉诊断以及长期治疗。新增章节涉及自发性冠状动脉夹层(SCAD)、非阻塞性冠状动脉心肌梗死(MINOCA)以及新引入的NSTE-ACS治疗质量指标。强调使用高敏心肌肌钙蛋白(hs-cTn)检测进行诊断检查,并建议采用快速分诊决策,以便在急诊室或胸痛单元早期确诊(非ST段抬高型心肌梗死)或排除(可能为NSTE-ACS)。在抗血小板治疗方面,建议根据个体缺血/血栓形成事件和出血并发症对治疗方案进行更大程度的个体化。在有创冠状动脉造影的时机方面引入了一些新内容;然而,原则上,极高危组仍应立即接受冠状动脉造影,高危组应在24小时内接受有创血管造影。在风险分层方面,原中间风险组已被取消,取而代之的是强调低危患者应与慢性冠状动脉综合征患者接受相似的治疗。